Aras C, Ozdamar A, Aktunç R, Erçikan C
Refractive Surgery Department, Istanbul University, Turkey.
Ophthalmic Surg Lasers. 1998 Aug;29(8):621-7.
To study the effect of topical prednisolone acetate after photorefractive keratectomy (PRK) using a 6.0-mm ablation diameter on the refractive and visual outcomes, corneal haze, corneal thickness, and corneal curvature in a prospective, double-masked, randomized manner.
Seventy-two eyes of 36 patients who had excimer laser PRK for correction of myopia ranging from -3.00 to -6.00 D (-4.11 +/- 0.84 D in eyes treated with steroids and -4.38 +/- 0.79 D in eyes treated with placebo; mean +/- SD) were enrolled. PRK procedures were performed using a 193-nm argon-fluoride excimer laser with 180-ml/cm2 fluence, a 10-Hz repetition rate, and a 6.0-mm ablation diameter. One eye of each patient was treated with the steroid (prednisolone acetate) and the other eye with placebo. Patients were observed for at least 12 months after PRK.
There was no statistically significant difference between the steroid and the placebo groups with regard to refraction measurements that were taken postoperatively at 3 months (P = .39) and 12 months (P = .51). The corneas showed an increase in thickness after PRK in both groups, but the difference was not statistically significant at 12 months postoperatively (P = .45). The corneal haze score was not statistically different at any stage between groups (P = .30 at 3 months, P = .84 at 12 months). Keratometric data derived from corneal topography did not show any statistically significant difference (P = .85 at 3 months, P = .96 at 12 months). The rate of uncorrected visual acuity of 20/40 or more was 79.4% (27 eyes) in the steroid group and 70.5% (24 eyes) in the placebo group (P = .40). The rate of loss of 2 or more lines in best spectacle-corrected visual acuity was 5.85% (2 eyes) in the steroid group and 8.8% (3 eyes) in the placebo group (P = 1.0).
Topical prednisolone acetate use for 3 months after PRK with a 6.0-mm ablation diameter has no effect on refractive and visual outcome, corneal haze, corneal thickness, and corneal curvature.
以前瞻性、双盲、随机的方式,研究准分子激光原位角膜磨镶术(PRK)后使用直径6.0毫米的消融区,局部应用醋酸泼尼松龙对屈光和视觉效果、角膜混浊、角膜厚度及角膜曲率的影响。
纳入36例患者的72只眼,这些患者接受准分子激光PRK治疗近视,近视度数范围为-3.00至-6.00 D(使用类固醇治疗的眼为-4.11±0.84 D,使用安慰剂治疗的眼为-4.38±0.79 D;均值±标准差)。使用193纳米氟化氩准分子激光进行PRK手术,能量密度为180 mJ/cm²,重复频率为10 Hz,消融直径为6.0毫米。每位患者的一只眼用类固醇(醋酸泼尼松龙)治疗,另一只眼用安慰剂治疗。PRK术后对患者观察至少12个月。
术后3个月(P = 0.39)和12个月(P = 0.51)时,类固醇组与安慰剂组在屈光测量方面无统计学显著差异。两组PRK术后角膜厚度均增加,但术后12个月时差异无统计学意义(P = 0.45)。两组在任何阶段的角膜混浊评分均无统计学差异(3个月时P = 0.30,12个月时P = 0.84)。角膜地形图得出的角膜曲率数据无统计学显著差异(3个月时P = 0.85,12个月时P = 0.96)。类固醇组未矫正视力达到20/40或更好的比例为79.4%(27只眼),安慰剂组为70.5%(24只眼)(P = 0.40)。类固醇组最佳矫正视力下降2行或更多行的比例为5.85%(2只眼),安慰剂组为8.8%(3只眼)(P = 1.0)。
PRK术后使用直径6.0毫米的消融区,局部应用醋酸泼尼松龙3个月,对屈光和视觉效果、角膜混浊、角膜厚度及角膜曲率无影响。